Navigation Links
New data on highly effective treatment for chronic rhinosinusitis with nasal polyps
Date:12/1/2009

December 1, 2009: OptiNose is pleased to announce the publication of results from its Phase II clinical study investigating the efficacy and tolerability of its novel, intranasal drug/device product for the topical treatment of chronic rhinosinusitis with nasal polyps in Rhinology, the official journal of the International and European Rhinologic Societies.

Chronic rhinosinusitis with nasal polyps is a chronic disease that can significantly reduce a patient's quality of life, causing facial pressure and pain, nasal obstruction and reduced sense of smell. The novel OptiNose device delivers drugs to target sites deep in the nose, including the sinus openings where nasal polyps emerge. These targets are often difficult to reach with traditional nasal sprays.

In the Phase II study conducted by OptiNose, patients in the active treatment group experienced highly significant reductions in polyp size compared to placebo with corresponding significant and progressive improvements of all symptom scores including rhinitis symptoms, nasal discomfort and sense of smell. At the conclusion of the study, the polyps had disappeared in 10 out of 54 patients in the active group, whereas polyps were still present in all patients in the control group.

The multicenter, placebo-controlled study, conducted in 109 patients with mild-to-moderate bilateral nasal polyposis, assessed the efficacy, safety and tolerability of 400 micrograms of fluticasone propionate delivered twice daily with OptiNose's liquid nasal drug delivery device over a 12 week period. Reduction in polyp size was measured using Lildholdt's Scale, a 4-point scale used to rate the size of nasal polyps. A significantly greater percentage of subjects using the OptiNose product showed a reduction in polyp size greater than or equal to 1 on the Lildholdt's Scale when compared to placebo at 4, 8 and 12 weeks (22% vs 7%, p = 0.011; 43% vs 7%, p < 0.001; 57% vs 9%, p < 0.001). The summed polyp score was reduced by 35% in the OptiNose treatment group after 12 weeks, compared to an increase in polyp score in the placebo group (-0.98 vs +0.23, p < 0.001). The peak nasal inspiratory airflow (PNIF) of subjects in the active group increased progressively during treatment (p < 0.001) and 76% of subjects treated were improved or very much improved after 12 weeks of treatment (p < 0.001).

"We are extremely pleased with these results", said ENT-specialist Per Djupesland, M.D., Ph.D., the study's co-author and Chief Scientific Officer at OptiNose AS. "This disease is difficult to treat and often recurs, even after repeated surgeries. Existing medical treatments offer only limited efficacy, especially on small and moderate sized polyps which are difficult to reach. The progressive reduction of small and moderate polyps in our study, including the complete removal in almost 20% of patients is particularly encouraging."

Chronic rhinosinusitis with nasal polyps is a common disease, severely reducing a patient's quality of life, with few effective treatments currently available. It is estimated that as much 10% of the population is affected by chronic rhinosinusitis, making it one of the most common chronic diseases. A substantial proportion (25-30%) of these patients suffer from nasal polyps and many undergo repeated costly surgeries. Improved medical treatment can reduce or eliminate the need for surgery. Furthermore, up to 50% of patients with nasal polyps suffer from asthma. Optimal treatment of chronic rhinosinusitis and nasal polyps can improve asthma symptoms and reduce the need for asthma medication.


'/>"/>

Contact: Helena Djupesland
Helena.Djupesland@optinose.no
472-295-8017
WFD Ventures
Source:Eurekalert

Related biology news :

1. Scientists unravel evolution of highly toxic box jellyfish
2. LMU Munich researchers highly endowed with EU funding
3. Forsyth receives highly competitive challenge grants
4. Duke biomedical scientists win 2 highly prized NIH Directors Awards
5. Lancet study supports new, highly effective treatment for blood disorder
6. New population of highly threatened greater bamboo lemur found in Madagascar
7. Slow-motion video study shows shrews are highly sophisticated predators
8. The key to unlocking the secret of highly specific DNAzyme catalysis
9. 454 Sequencing: Science paper describes a novel, highly efficient method of sequencing ancient DNA
10. A sticky solution for identifying effective probiotics
11. Carnegie Mellon customizing electric cars for cost-effective urban commuting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/13/2017)... 2017 UBM,s Advanced Design and Manufacturing event ... emerging and evolving technology through its 3D Printing and ... alongside the expo portion of the event and feature ... focused on trending topics within 3D printing and smart ... event will take place June 13-15, 2017 at the Jacob ...
(Date:4/11/2017)... Florida , April 11, 2017 ... a security technology company, announces the appointment of independent Directors ... Bendheim to its Board of Directors, furthering the company,s ... ... of NXT-ID, we look forward to their guidance and benefiting ...
(Date:4/4/2017)... April 4, 2017   EyeLock LLC , a ... the United States Patent and Trademark Office (USPTO) has ... the linking of an iris image with a face ... represents the company,s 45 th issued patent. ... very timely given the multi-modal biometric capabilities that have ...
Breaking Biology News(10 mins):
(Date:10/10/2017)... ... 10, 2017 , ... The Pittcon Program Committee is pleased ... scientists who have made outstanding contributions to analytical chemistry and applied spectroscopy. Each ... leading conference and exposition for laboratory science, which will be held February 26-March ...
(Date:10/9/2017)... ... 2017 , ... The award-winning American Farmer television series will feature 3 Bar ... Tuesdays at 8:30aET on RFD-TV. , With global population estimates nearing ten billion ... continue to feed a growing nation. At the same time, many of our valuable ...
(Date:10/9/2017)... ... 09, 2017 , ... The Giving Tree Wellness Center announces ... needs of consumers who are incorporating medical marijuana into their wellness and health ... As operators of two successful Valley dispensaries, The Giving Tree’s two founders, Lilach ...
(Date:10/7/2017)... , ... October 06, 2017 ... ... experience providing advanced instruments and applications consulting for microscopy and surface analysis, ... in application consulting, Nanoscience Analytical offers a broad range of contract analysis ...
Breaking Biology Technology: